Latest News

    • Eyestem is awarded the prestigious Biotechnology Ignition Grant (BIG) from BIRAC

      Eyestem is delighted to announce the receipt of the BIG grant from BIRAC, Government of India. The BIG grant is considered among the most prestigious grants for start-ups in the biotech space because it involves a three-tiered review panel of some of the most eminent scientists in the country and typically has over 250 applicants in a single grant call.

      The grant is to further ERPL’s research into 2D (in monolayer) photoreceptors and 3D (in suspension) retinal organoids- both of which are growing efficiently through a patented process in the Eyestem lab. Further studies in the Crx knockout mouse model will provide valuable insights into the potential of such therapy to be robust and efficacious.
      For further information, please write to info@eyestem.com

    • Eyestem files a patent for a unified protocol for co-creation of Retinal Pigment Epithelium progenitors (RPE-P) and Photoreceptor progenitors (PR-P)

      Eyestem Research (ERPL), a company engaged in creating cell therapies for incurable diseases of the eye today filed a patent to create both its products: RPE-P and PR-P: through a unified protocol. By employing this protocol, ERPL has demonstrated that a large part of the process of the creation of the two products remain exactly the same.

      Having a unified methodology will allow ERPL to create both products with a scalable and affordable process. This is a highly significant advancement whose potential will be fully realized in the coming years when the company moves to GMP production at scale for patients.

      For further information, please write to info@eyestem.com

    • Eyestem Research Private Limited enters into a research collaboration with Nxcell Inc. for testing its Photoreceptor progenitors (PR-P) in the Crx mouse model

      Eyestem Research (ERPL), a company engaged in creating cell therapies for incurable diseases of the eye, today announced a research collaboration with Nxcell Inc. for testing its cell based product for Retinitis Pigmentosa. Eyestem’s product is a patented cell suspension of Photoreceptor progenitors (PR-P) and will be tested for efficacy in the Crx knockout mouse model.

      The collaboration between ERPL and Nxcell will be enabled by Dr. Deepak Lamba, Associate Professor for vision research at the Buck Institute, Los Angeles. Dr. Lamba serves on the scientific board of Eyestem and has published several seminal papers in efficacy of photoreceptors in rescuing and reversing vision loss in mice models. The outcome of this experiment will enable ERPL to create efficacy data that is globally acceptable and move its product forward in clinical trials.

      For more information, please e-mail us at info@eyestem.com

    • Eyestem Research Private Limited enters into a research collaboration with Oregon Health & Science University to test its Retinal Pigment Epithelium progenitor (RPE-P) product for Age-related Macular Degeneration in the RCS rat model

      Eyestem Research (ERPL), a company engaged in creating cell therapies for incurable diseases of the eye, today announced a research collaboration with OHSU in Portland, Oregon, for testing its cell based product for Age-related Macular Degeneration. Eyestem’s product is a patented cell suspension of Retinal Pigment Epithelium progenitors (RPE-P) and will be tested for efficacy in the Royal College of Surgeons (RCS) rat model.
      The collaboration will enable ERPL to work with Trevor McGill, Ph.D., a recipient of the 2017 Carolyn K. McGillvray Award for Macular Degeneration Research. Dr. McGill’s expertise with the disease model and his involvement in several IND-enabling studies will enable ERPL to collect data that is globally acceptable for the efficacy of its RPE-P product.

      For more information, please e-mail us at info@eyestem.com